Almatroodi S, McDonald C, Darby I, Pouniotis D (2016) Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron 9(1): 1–11.
Antonia S, Rizvi N, Brahmer J, Ou S-H, Khleif SN, Hwu W-J, Gutierrez M, Schoffski P, Hamid O, Weiss J (2016) Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Res 4(1 Supplement): A047–A047.
Banat G-A, Tretyn A, Pullamsetti SS, Wilhelm J, Weigert A, Olesch C, Ebel K, Stiewe T, Grimminger F, Seeger W (2015) Immune and inflammatory cell composition of human lung cancer stroma. PLoS One 10(9): e0139073.
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit E, Syrigos K, Stahel R (2014) 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 25(8): 1475–1484.
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, Jack RS, Wunderlich FT, Brüning JC, Müller W (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34(4): 566–578.
Chen S, Ni G, Wu X, Zhu B, Liao Z, Wang Y, Liu X (2016a) Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice. Cell Immunol 300: 9–17.
Chen W-J, Hu X-F, Yan M, Zhang W-Y, Mao X-B, Shu Y-W (2016b) Human umbilical vein endothelial cells promote the inhibitory activation of CD4+ CD25+ Foxp3+ regulatory T cells via PD-L1. Atherosclerosis 244: 108–112.
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917): 860–867.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1): 11–20.
Dennis KL, Blatner NR, Gounari F, Khazaie K (2013) Current status of IL-10 and regulatory T-cells in cancer. Curr Opin Oncol 25(6): 637.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ (2016) NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw 14(3): 255–264.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5): E359–E386.
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13): 3015–3029.
Fry WA, Phillips JL, Menck HR (1999) Ten–year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 86(9): 1867–1876.
Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLS One 7(2): e30676.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L Committee IAftSoLCIS (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8): 706–714.
Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T (2000) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11(7): 815–819.
Hatanaka H, Abe Y, Naruke M, Tokunaga T, Oshika Y, Kawakami T, Osada H, Nagata J, Kamochi J-i, Tsuchida T (2001) Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res 7(5): 1287–1292.
Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM (1998) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58(6): 1208–1216.
Hubackova S, Kucerova A, Michlits G, Kyjacova L, Reinis M, Korolov O, Bartek J, Hodny Z (2016) IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. Oncogene 35(10): 1236–1249.
Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177(2): 896–904.
Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W, Shi H, Jiang J, Wu C (2016) PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 17(4): 407–413.
Jiang L, Su X, Zhang T, Yin X, Zhang M, Fu H, Han H, Sun Y, Dong L, Qian J (2016) PD-L1 expression and its relationship with other driver genes in non-small cell lung cancer (NSCLC) Cancer Res 76(14 Suppl): ): abstract 5140.
Ke X, Zhang S, Xu J, Liu G, Zhang L, Xie E, Gao L, Li D, Sun R, Wang F (2016) Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation. Cancer Immunol Immunother 65(5): 587–599.
Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Kudo-Saito C (2016) Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small cell lung cancer. Ann Oncol 27(11): 2117–2123.
Kirby KS (1956) A new method for the isolation of ribonucleic acids from mammalian tissues. Biochem J 64(3): 405–408.
Krneta T, Gillgrass A, Poznanski S, Chew M, Lee AJ, Kolb M, Ashkar AA (2017) M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J Leuk Biol 101(1): 285–295.
Kuang DM, Zhao QY, Peng C, Xu J, Zhang JP, Wu CY, Zheng LM (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6): 1327–1337.
Lin Y-C, Lin C-K, Tsai Y-H, Weng H-H, Li Y-C, You L, Chen J-K, Jablons DM, Yang C-T (2010) Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells. Oncol Rep 24(6): 1605.
Llorente L, Richaud–Patin Y, García–Padilla C, Claret E, Jakez–Ocampo J, Cardiel MH, Alcocer–Varela J, Grangeot–Keros L, Alarcón–Segovia D, Wijdenes J (2000) Clinical and biologic effects of anti–interleukin–10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43(8): 1790–1800.
Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I (2016) Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro-and antitumor immunity. Clin Cancer Res 22(10): 2329–2334.
Montuenga L, Pio R (2007) Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30(4): 608–610.
Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR (2016a) Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34(29): 3562–3569.
Naing A, Papadopoulos KP, Infante JR, Wong DJ, Autio KA, Ott PA, Falchook GS, Patel M, Pant S, Patnaik A (2016b) Clinical activity and safety of PEGylated human IL-10 (AM0010) in combination with anti-PD-1. Cough 2: 15.
Naruke T, Goya T, Tsuchiya R, Suemasu K (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96(3): 440–447.
Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, Wang Y, Wei MQ, Liu X (2015) Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol 293(2): 126–129.
Petrovic M, Cekerevac I, Lazic Z, Zdravkovic V (2013) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Eur Respir J 42(Suppl 57): P2916.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19): 1823–1833.
Rybojad P, Jabłonka A, Wilczyńska B, Tabarkiewicz J (2013) Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. Eur J Surg Oncol 39(11): 1269–1277.
Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM (1999) T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 163(9): 5020–5028.
Staples KJ, Smallie T, Williams LM, Foey A, Burke B, Foxwell BM, Ziegler-Heitbrock L (2007) IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J Immunol 178(8): 4779–4785.
Sundar R, Cho B-C, Brahmer JR, Soo RA (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7(2): 85–96.
Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75(1): 95–101.
Teng MW, Darcy PK, Smyth MJ (2011) Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell 20(6): 691–693.
Wang R, Lu M, Chen H, Chen S, Luo X, Qin Y, Zhang J (2011) Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J ExpClin Cancer Res 30(1): 1.
Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6): 492–499.
Zeng L, O’Connor C, Zhang J, Kaplan AM, Cohen DA (2010) IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 49(3): 294–302.
Zeni E, Mazzetti L, Miotto D, Cascio NL, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri L, Mapp C (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4): 627–632.
Zhang H, Wang Y, Hwang ES, He Y-W (2016) Interleukin-10: an immune-activating cytokine in cancer immunotherapy. J Clin Oncol 34(29): 3576–3578.
Zhang L, Gajewski TF, Kline J (2009) PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114(8): 1545–1552.
Zun-Qiang Zhou D-NT, Guan J, Tan H-W, Zhao L-D, Zhu Y, Yao J, Yang J, Zhang Z-Y (2016) Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. Am J Transl Res 8(7): 2926.